Engineered immune cells take on Hard-to-Treat blood cancers
NCT ID NCT06191887
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called BAFFR on cancer cells, and infusing them back along with chemotherapy. The main goals are to find the safest dose and to watch for side effects in 27 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAFFR-targeting CAR T cells (MC10029) with chemotherapy (fludarabine and cyclophosphamide)
- What this could lead to
- If it works, this could offer a new treatment option for patients with B-cell cancers that have come back or stopped responding to standard therapy.
- What could go wrong
- This is a very early (Phase 1) trial with only 27 participants, so it is mainly checking safety and dosing. The treatment may not work, and side effects like cytokine release syndrome or nervous system problems are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- Can a single shot build a cancer army inside the body?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?